GlassScriptPhysician profile
James Mccauley
NPI 1700870367
$4,519.70
in general payments reported to CMS, 2019-2025
27 companies · $691 in 2025
The $691 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,067 · 2020: $377 · 2021: $75.62 · 2022: $428 · 2023: $934 · 2024: $947 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,571.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,467.18 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $620.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.94 | 2019-2025 | Jardiance |
| Pfizer INC. | $278.84 | 2019-2025 | |
| Amgen INC. | $252.42 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $208.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $184.04 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $156.11 | 2019-2024 | Capvaxive |
| Exact Sciences Corporation | $154.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $148.48 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $127.26 | 2019-2022 | |
| Astellas Pharma US INC | $103.73 | 2019-2025 | Veozah |
| Abbvie INC. | $92.92 | 2021-2025 | |
| Inspire Medical Systems, INC. | $66.31 | 2023 | Inspire |
| Sumitomo Pharma America, INC. | $58.00 | 2023-2024 | Gemtesa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $56.49 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.98 | 2023-2024 | Trulance, Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $31.07 | 2022 | |
| Phathom Pharmaceuticals, INC. | $29.17 | 2024 | Voquezna |
| Insmed, INC. | $27.17 | 2023 | Arikayce |
| Avanir Pharmaceuticals, INC. | $23.53 | 2019 | |
| Boston Scientific Corporation | $22.24 | 2019 | |
| Allergan, INC. | $19.81 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.90 | 2019 | |
| Currax Pharmaceuticals LLC | $14.88 | 2023 | Contrave, Onzetra Xsail |
| Amarin Pharma, INC. | $12.96 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mccauley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.